Psychedelic Institute of Mental Health & Family Therapy
Psychedelic Institute of Mental Health & Family Therapy
Telehealth Ketamine Therapists
⌘K
Contact
Psychedelic Institute of Mental Health & Family Therapy
ketamine

Spotlight: Brain changes associated with depression treatment: a meta-analysis

Meta-analysis of data from 302 depressed subjects yielding 87 foci across 18 experiments examining various depression treatments including pharmacology, psychotherapy, electroconvulsive therapy, psilocybin, and ketamine with brain activity measures in response to emotion tasks in the scanner.
Michael DeMarco, PhD

by Michael DeMarco, PhD

Brain changes associated with depression treatment: a meta-analysis - PubMed
Our result, focusing on within-patient changes associated with treatment, highlights the right amygdala as a brain area especially relevant to depression treatment measured with fMRI. This finding provides a lens to focus depression biomarker research based on imaging measures that track depression …
PubMedGianna M Perez

(2025) Meta-analysis of data from 302 depressed subjects yielding 87 foci across 18 experiments examining various depression treatments including pharmacology, psychotherapy, electroconvulsive therapy, psilocybin, and ketamine with brain activity measures in response to emotion tasks in the scanner. Our result, focusing on within-patient changes associated with treatment, highlights the right amygdala as a brain area especially relevant to depression treatment measured with fMRI. This finding provides a lens to focus depression biomarker research based on imaging measures that track depression treatment effects.

More like this

Spotlight: Comparing the Cognitive Effects of Repeated Intravenous Ketamine and Electroconvulsive Therapy in Patients With Treatment-Resistant Depression: A Secondary Analysis of the ELEKT-D Trial

"Patients treated with ketamine demonstrated superior cognitive functioning compared with ECT following a 3-week treatment, no differences between treatments observed. Findings support short-term superiority of ketamine on cognitive functioning and the long-term cognitive safety of both treatments."

Spotlight: Harriet de Wit: What can we learn about behavior and brain processes by studying psychoactive drugs in humans?

"her laboratory demonstrated that MDMA enhances feelings of social connectedness during interpersonal interactions, findings that have profound implications for PTSD treatment and psychotherapy."

Spotlight: Psychedelics and mental health: reimagining care through science, insight, and compassion (Mikellides, et al, 2025)

"These substances are not stand-alone medications; rather, they function as adjuncts to intensive psychotherapeutic processes. Training therapists and establishing ethical, evidence-based protocols is essential."

Spotlight: Investigating the safety and tolerability of single-dose psilocybin for post-traumatic stress disorder: A nonrandomized open-label clinical trial (McGowan, et al, 2025)

"In this trial, COMP360 psilocybin administered in a single session with psychological support was found to be generally well-tolerated and without serious risk to safety... treatment associated with rapid, sustained reduction in PTSD symptoms, improved functioning and quality of life to 12 weeks"

Spotlight: NMDA receptor-modulating treatments for cognitive deficits in patients with bipolar disorder: A narrative review (Badrfam, et al, 2025)

"Ketamine infusions have improved processing speed and verbal learning in bipolar disorder patients. Evidence suggests that NMDA receptor-modulating agents play a significant role in improving cognitive function in patients with bipolar disorder. "

Spotlight: Nonresponse to Ketamine in Treatment-Resistant Bipolar Depression (Kachlick, et al, 2025)

Ketamine demonstrates a favorable safety and tolerability profile for short time use in TRBD regardless of isolated baseline characteristics, although a more severe comorbidity burden and benzodiazepine use appear to be associated with nonresponse.
Mastodon Mastodon